Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.04 (-28.68%)
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
Senti Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Senti Biosciences's operating margin for the twelve months ending Jun 30, 2024 was -27287.3%. For fiscal 2025 it was -312631.8%, against -3620.7% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -312631.8% | −309011.1 |
| FY2023 | Dec 31, 2023 | -3620.7% | −2172.2 |
| FY2022 | Dec 31, 2022 | -1448.5% | +16.4 |
| FY2021 | Dec 31, 2021 | -1464.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -85229.4% | −84065.8 |
| Q1 FY2026 | Mar 31, 2026 | -28850.0% | −385.6 |
| Q3 FY2023 | Sep 30, 2023 | -12981.1% | −12146.0 |
| Q2 FY2023 | Jun 30, 2023 | -1620.9% | −17.8 |
| Q1 FY2023 | Mar 31, 2023 | -1163.6% | −98.6 |
| Q4 FY2022 | Dec 31, 2022 | -28464.4% | −27091.8 |
| Q3 FY2022 | Sep 30, 2022 | -835.1% | +200.5 |
| Q2 FY2022 | Jun 30, 2022 | -1603.2% | −468.7 |
| Q1 FY2022 | Mar 31, 2022 | -1065.0% | – |
| Q4 FY2021 | Dec 31, 2021 | -1372.6% | – |
| Q3 FY2021 | Sep 30, 2021 | -1035.6% | – |
| Q2 FY2021 | Jun 30, 2021 | -1134.4% | – |
See a number that looks wrong?